ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ACRS Company Profile and Key Details

NASDAQ : ACRS

Aclaris Therapeutics, Inc.

$1.83

0.01+0.55%

At Close 4:00 PM

72.81

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

ACRS Stock Price Chart

Stock Price Today

Aclaris Therapeutics, Inc. (ACRS) stock surged +0.55%, trading at $1.83 on NASDAQ, up from the previous close of $1.82. The stock opened at $1.88, fluctuating between $1.82 and $2.03 in the recent session.

Stock Snapshot

1.82

Prev. Close

1.88

Open

197.49M

Market Cap

107.92M

Number of Shares

1.82

Day Low

2.0275

Day High

-1.07

P/E Ratio

84.7%

Free Float in %

-1.71

EPS (TTM)

2.22

Book Value

-1.12

Cash Flow per Share

1.15M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 07, 2025	1.88	2.03	1.82	1.83	1.2M
Mar 06, 2025	1.77	1.87	1.75	1.82	648.76K
Mar 05, 2025	1.92	1.96	1.84	1.85	439.99K
Mar 04, 2025	1.88	1.97	1.86	1.93	622.25K
Mar 03, 2025	2.01	2.09	1.94	1.96	547.57K
Feb 28, 2025	1.90	2.02	1.77	1.99	1.1M
Feb 27, 2025	2.17	2.17	1.94	1.95	640.74K
Feb 26, 2025	2.07	2.13	2.05	2.10	636.8K
Feb 25, 2025	2.07	2.09	2.00	2.06	510.63K
Feb 24, 2025	2.23	2.25	2.05	2.07	495.99K
Feb 21, 2025	2.29	2.34	2.22	2.24	371.04K
Feb 20, 2025	2.33	2.34	2.24	2.31	354.82K
Feb 19, 2025	2.30	2.42	2.26	2.31	610.01K
Feb 18, 2025	2.35	2.38	2.24	2.30	423.3K
Feb 14, 2025	2.18	2.35	2.17	2.33	473.7K
Feb 13, 2025	2.19	2.24	2.14	2.20	388.06K
Feb 12, 2025	2.13	2.22	2.11	2.17	726.12K
Feb 11, 2025	2.37	2.37	2.19	2.20	412.71K
Feb 10, 2025	2.54	2.55	2.38	2.39	603.77K
Feb 07, 2025	2.46	2.54	2.40	2.49	715.2K

Contact Details

Wayne, PA 19087

United States

Website: https://www.aclaristx.comContact: 484 324 7933

About Company

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Frequently Asked Questions

What is the current Aclaris Therapeutics, Inc. (ACRS) stock price?

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) stock price is $1.83 in the last trading session. During the trading session, ACRS stock reached the peak price of $2.03 while $1.82 was the lowest point it dropped to. The percentage change in ACRS stock occurred in the recent session was 0.55% while the dollar amount for the price change in ACRS stock was $0.01.

ACRS's industry and sector of operation?

The NASDAQ listed ACRS is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Aclaris Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACRS?

Mr. Matthew Rothman J.D.
Gen. Counsel & Corporation Sec.
Dr. Gail Cawkwell M.D., Ph.D.
Chief Medical Officer
Mr. Frank Ruffo
Co-Founder, Chief Financial Officer , Sec. & Treasurer
Mr. Robert A. Doody Jr.
Vice President of Investor Relations
Dr. Paul S. Changelian Ph.D.
Senior Vice President of Biology
Dr. Neal S. Walker D.O.
Co-Founder & Chairman
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Dr. Douglas J. Manion Frcp(C), M.D.
Chief Executive Officer, Pres & Director
Dr. Joseph Monahan
Chief Scientific Officer
Mr. James Loerop
Chief Bus. Officer
Dr. Ian Anderson Ph.D.
Executive Vice President of Translational R&D
Mr. Gary A. DeCrescenzo
Senior Vice President of Pharmaceutical R&D
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer

How ACRS did perform over past 52-week?

ACRS's closing price is 92.23% higher than its 52-week low of $0.95 where as its distance from 52-week high of $5.17 is -64.6%.

How many employees does ACRS have?

Number of ACRS employees currently stands at 61.

Link for ACRS official website?

Official Website of ACRS is: https://www.aclaristx.com

How do I contact ACRS?

ACRS could be contacted at phone 484 324 7933 and can also be accessed through its website. ACRS operates from 640 Lee Road, Wayne, PA 19087, United States.

How many shares of ACRS are traded daily?

ACRS stock volume for the day was 1.15M shares. The average number of ACRS shares traded daily for last 3 months was 813.02K.

What is the market cap of ACRS currently?

The market value of ACRS currently stands at $197.49M with its latest stock price at $1.83 and 107.92M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	61
Beta	0.5
Sales or Revenue	$31.25M
5Y Sales Change%	0.46%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research